# A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight

> **NCT07441252** · PHASE2 · RECRUITING · sponsor: **Amgen** · enrollment: 180 (estimated)

## Conditions studied

- Overweight or Obesity and Elevated Liver Fat

## Interventions

- **DRUG:** Maridebart cafraglutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07441252
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-05
- **Primary completion:** 2027-09-29
- **Final completion:** 2027-12-22
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07441252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07441252, "A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07441252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*